"Without question, BioAdvance funding was a critical ingredient for the launch of Melior Discovery. There was simply no comparable funding source for a startup entity such as ours. Melior would not exist today, would not have discovered a new class of candidate diabetes therapeutics, and would not have uncovered new clinical candidates for our pharma partners were it not for funding conduit provided by BioAdvance."
Andrew Reaume
President & CEO
Melior Discovery, Inc.
Exton, PA
Andrew Reaume
President & CEO
Melior Discovery, Inc.
Exton, PA
News Releases
| 2009 | | | 2008 | | | 2007 | | | 2006 | | | 2005 | | | 2004 | | | 2003 | | | 2002 | | | 2001 |
2009
|
October 30, 2008 Jenrin's Non-Brain Penetrant CB1 Antagonist Shows Beneficial Effects in Treating Diabetes an Obesity |
| > View Press Release |
|
September 12, 2008 BioAdvance to Invest $1.5M in Three New Life Sciences Companies |
| > View Press Release |
|
July 24, 2008 NuPathe Closes $30M Series B Financing |
| > View Press Release |
|
May 2, 2008 Protez Initiates Phase II Study for Its Lead Product PZ-601In Infectious Diseases |
| > View Press Release |
|
February 26, 2008 CollaGenex Signs Merger Agreement with Galderma S.A. |
| > View Press Release |
|
February 25, 2008 Marillion Pharmaceuticals and Cytokine PharmaScience Announce License Agreement for Xerostomia Treatment |
| > View Press Release |
|
February 8, 2008 John Gill and Steven Nichtberger, M.D. Join BioAdvance Board |
| > View Press Release |
|
January 7, 2008 Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRVIII Vaccine for Glioblastoma |
© Copyright 2008. BioAdvance, the Biotechnology Greenhouse of Southeastern Pennsylvania. All Rights Reserved.